GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster
September 11, 2023 09:00 ET
|
GeoVax, Inc.
Multi-antigen Vaccine Designed to Protect Against Evolving SARS-CoV-2 Variants ATLANTA, GA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update
August 09, 2023 16:00 ET
|
GeoVax, Inc.
Progress and Promising Outlook for Gedeptin® and GEO-CM04S1; Phase 2 GEO-CM04S1; Clinical Trial Initiated for Patients with Chronic Lymphocytic Leukemia Company to Host Conference Call and Webcast...
GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference
June 28, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, June 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates
May 31, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, May 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax to Participate in Upcoming Industry Meetings
May 25, 2023 09:00 ET
|
GeoVax, Inc.
Management to participate in 2023 ASCO Annual Meeting and 2023 BIO International Convention ATLANTA, GA, May 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients
May 24, 2023 08:00 ET
|
GeoVax, Inc.
New and Unpublished Data from Phase 2 Open-Label Safety Study ofGEO-CM04S1 Presented at Two Recent Scientific Meetings ATLANTA, GA, May 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs,...
GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update
May 04, 2023 16:00 ET
|
GeoVax, Inc.
Cancer Gene Therapy Program and Next-Generation COVID-19 VaccineAdvancing in Phase 2 Clinical Trials Company to Host Conference Call and Webcast Today at 4:30...
GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023
April 25, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, April 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and...
GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses
April 17, 2023 09:00 ET
|
GeoVax, Inc.
Expanded Rights Include Development of GEO-CM04S1 Against Mpox (Monkeypox) and Smallpox ATLANTA, GA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update
March 23, 2023 16:00 ET
|
GeoVax, Inc.
Company Expands Ongoing Clinical Trials and theBreadth and Capacity of Its Novel Vaccine Platform Technology ATLANTA, GA, March 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs,...